Key result
Nine out of 41 tested isoquinoline alkaloids exhibited significant inhibitory activity towards ADP-, AA-, collagen-, and/or PAF-induced platelet aggregation in vitro.
Several isoquinoline alkaloids demonstrate significant in vitro antiplatelet aggregation activity, providing insights into structure-activity relationships for potential novel antiplatelet agents.
Does not support clinical use; leaves open antiplatelet potential pending in vivo validation.
Forty-one isoquinoline alkaloids were tested for antiplatelet aggregation effects. Among them, (-)-discretamine (6), protopine (7), ochotensimine (18), O-methylarmepavinemethine (23), lindoldhamine (25), isotetrandrine (26), thalicarpine (27), papaverine (28), and D-(+)- N-norarmepavine (32) exhibited significant inhibitory activity towards adenosine 5'-diphosphate (ADP)-, arachidonic acid (AA)-, collagen-, and/or platelet-activating factor (PAF)-induced platelet aggregation. The results are discussed on the basis of structure-activity relationships.
No takes yet. Share an insight, caveat, or question.
Chia et al. (2006) studied Platelet aggregation. Isoquinoline alkaloids was evaluated on Inhibition of ADP-, AA-, collagen-, and/or PAF-induced platelet aggregation. Nine out of 41 tested isoquinoline alkaloids exhibited significant inhibitory activity towards ADP-, AA-, collagen-, and/or PAF-induced platelet aggregation in vitro.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: